코아스템켐온
Financials
Valuation Metrics
코아스템켐온's Market Cap is ₩1053B. At end of 2025 it was ₩977B. Ranked #1217 of 2,436 in KR market (top 50%), #647 of 1,649 on KOSDAQ (top 39%), #139 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 105.26B KRW | KR#1,217/2,436 Sec#139/234 |
| Revenue | 18.39B KRW | KR#2,159/2,436 Sec#158/234 |
| Net Income | -31.99B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 105.58B KRW | KR#1,703/2,436 Sec#138/234 |
| Net Assets | 48.15B KRW | KR#1,902/2,436 Sec#164/234 |
| Employees | 376 | KR#644/2,436 Sec#56/234 |
| Value | ||
| P/B | 2.19x | KR#1,991/2,436 Sec#148/234 |
| P/S | 5.72x | KR#2,175/2,436 Sec#144/234 |
| FCF Yield | -15.13% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -66.44% | KR#2,303/2,436 Sec#210/234 |
| ROA | -30.30% | KR#2,304/2,436 Sec#200/234 |
| Op. Margin | -126.97% | KR#2,327/2,436 Sec#181/234 |
| Revenue Growth | -28.96% | KR#2,162/2,436 Sec#197/234 |
| Earnings Growth | -787.94% | KR#1,674/2,436 Sec#114/234 |
| Financial Health | ||
| Debt Ratio | 219.29% | KR#1,833/2,436 Sec#198/234 |
| Total Debt | 36.56B KRW | KR#1,104/2,436 Sec#81/234 |
| FCF | -15.92B KRW | KR#1,841/2,436 Sec#171/234 |
| Cash | 2.76B KRW | KR#2,178/2,436 Sec#208/234 |
| Current Ratio | 0.28x | KR#2,331/2,436 Sec#229/234 |
| Performance | ||
| 1Y Return | -16.83% | KR#1,204/2,436 Sec#97/234 |
| 1M Return | -6.31% | KR#1,546/2,436 Sec#148/234 |
| From 52W High | -67.36% | KR#2,031/2,436 Sec#175/234 |
| 1Y MDD | -65.79% | KR#1,738/2,436 Sec#145/234 |
| Trading | ||
| Volume | 116,121 shares | KR#1,023/2,436 Sec#95/234 |
| Foreign Own. | 2.04% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -729 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,005 KRW | KR#2,282/2,436 Sec#204/234 |
Company Info
Established in 2003 and listed on KOSDAQ in 2015, Corestem ChemOn merged with Kellun Co., Ltd., a top-three domestic non-clinical Contract Research Organization, in 2022. The company specializes in the production and sale of treatments for rare and intractable diseases based on stem cell technology, successfully commercializing stem cell therapies since 2015. It collaborates with clinical centers to develop and rapidly commercialize cell therapies, aiming to become a global leader through overseas license-out agreements and expanded indications. Corestem ChemOn is headquartered in Seongnam-si, Gyeonggi-do.